Concentric-Risk-Security-Management near Delta BC (418 Result(s))

Action Travel And Our Agents, Joy, Jeanette And Gisela Have Over 20 Years Of Experience Working On Travel Bookings One On One With Clients Just Like Yourselves. You Can Still Book From The Comfort Of Your Office Or Home And Still Have A Dedicated Agent Working On Your Behalf. There Is No Additional Cost For Working With An Agent And In Many Cases It Will Save You Money. To Us Your Travel Starts The Minute You Pick Up The Phone. Enjoy Your Travel Experience By Letting Us Take On The Hassles Of Getting To That Business Meeting Or Planning That Dream Vacation. We Work With You Until You Have Exactly What You Want Whether It Is A Quick Business Trip, An Escorted Or Custom Tour Or A Custom Tour Program For A Group.

Sam Sullivan, founder of the Disability Foundation.The Disability Foundation and its affiliated organizations were founded by Sam Sullivan after he became teraplegic as a result of a skiing accident at the age of 19. The foundation provides opportunities for people with disabilities. It promotes the capabilities and talents of people with physical challenges, once barriers in the physical landscape have been overcome.The Tetra Society recruits technically skilled volunteers who have made more than 5,000 custom-made assistive devices for people with disabilities in locations throughout North America. ConnecTra Society serves as a connecting agency, linking people with physical disabilities to activities and programs . The Disabled Sailing Association has catalyzed the formation of 20 sailing programs throughout North America and has 140 of its specially designed sip and puff 16-foot sailboats in use throughout the world (and now has its own boat donation site and blog, Sailing is Freedom )

Erickson Coaching pioneers coach training with new and innovative courses, masterful training, and technologically superior online learning. Find out how we stand out from our competitors. 34 years delivering human development programs. ICF accredited. Tools and resources to keep you connected

We are a clinical-stage pharmaceutical company discovering and developing novel oral drug candidates to treat inflammation and cancer. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Our lead product candidate, AQX-1125, has demonstrated broad anti-inflammatory activity in vitro and in vivo, and has successfully completed three clinical trials with over 100 patients enrolled to date. We are currently investigating AQX-1125 in two Phase 2 clinical trials, one for exacerbations related to Chronic Obstructive Pulmonary Disease, or COPD, and one for Bladder Pain Syndrome/Interstitial Cystitis, or BPS/IC. COPD and BPS/IC are debilitating chronic inflammatory diseases affecting millions of people worldwide.